ADAMTS13 and obstructive sleep apnea syndrome: Additionally, circulating ADAMTS13 levels were significantly increased in OSA patients compared with controls (0.8 (range, 0.5–1.7) μg/mL vs. 2.7 (range 2.2–3.2) μg/mL, respectively, P < 0.001) (Figure 2).